Contact Congress about S. 652: Protecting Patients from Deceptive Drug Ads Act
People paid to promote prescription drugs online could face penalties for false or incomplete posts. The bill would also make more promotion payments public and fund federal monitoring of social media drug ads.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Protecting Patients from Deceptive Drug Ads Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130).
Latest action on S. 652: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130)
Who this affects: This bill mainly affects people and businesses paid to promote prescription drugs online. Influencers, health care providers, and some telehealth companies would face new risks if their paid posts leave out required safety facts or mislead people. Drug makers and federal agencies would also have new reporting, monitoring, and enforcement roles.
Why this matters: Many people see drug information first on social media, and paid posts can look like personal advice. This bill would make those posts riskier when they are false, misleading, or missing required safety facts. It could also help the public see who is being paid to promote drugs. At the same time, its impact would depend on how agencies write the guidance, use monitoring tools, and enforce the new rules.
Key provisions in S. 652
- Creates a new money penalty for paid social media drug promotions. It applies to influencers and health care providers who knowingly or recklessly make false or misleading posts about certain prescription or compounded drugs.
- Explains what counts as false or misleading. A post can violate the rule if it gives wrong facts, leaves out important facts, or skips a required short safety summary about risks and effectiveness.
- Protects normal medical speech from the new penalty rule. This includes real patient care, real medical research statements, and true personal experience, opinion, or value judgment.
- Requires Health and Human Services to explain the new penalty rules within 180 days. The guidance must give examples of likely problems and explain how different social media platforms will be considered.
- Adds some telehealth-related advertisers to prescription drug ad rules. This applies when they advertise a specific prescription or compounded drug and use technology to connect possible patients with prescribers or pharmacies.
How Modern Action helps you take action on S. 652
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Questions people ask about S. 652
- What is S. 652?
- People paid to promote prescription drugs online could face penalties for false or incomplete posts. The bill would also make more promotion payments public and fund federal monitoring of social media drug ads.
- How do I support or oppose S. 652?
- Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
- Who should I contact about S. 652?
- Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
- Can Modern Action explain S. 652 before I act?
- Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.
